Showing results (31-40 of 2,288) with videos related to
Sort By:
Pageof 229
Cancer Research and Treatment|December 5, 2017
HBsAg-Negative, Anti-HBc-Negative Patients Still Have a Risk of Hepatitis B Virus-Related Hepatitis after Autologous Stem Cell Transplantation for Multiple Myeloma or Malignant LymphomaHyunsung Park, Do Young Kim, Soo-Jeong Kim, et al.Cancer Research and Treatment|December 26, 2018
Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric CancerJin Won Kim, Jong Gwang Kim, Byung Woog Kang, et al.Cancer Research and Treatment|May 6, 2021
The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by SurgeryHyehyun Jeong, Kye Jin Park, Yongjune Lee, et al.Cancer Research and Treatment|May 4, 2021
Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01)Yun-Gyoo Lee, Eun Joo Kang, Bhumsuk Keam, et al.Cancer Research and Treatment|September 14, 2021
Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung CancerHyun-Seock Shin, Juwhan Choi, Jinhwan Lee, et al.Cancer Research and Treatment|October 25, 2019
Prevalence and Clinicopathological Significance of MET Overexpression and Gene Amplification in Patients with Gallbladder CarcinomaYeseul Kim, Seong Sik Bang, Seungyun Jee, et al.Cancer Research and Treatment|August 20, 2021
A Real-world Efficacy of Nab-paclitaxel Monotherapy in Metastatic Breast CancerJung Sun Kim, Koung Jin Suh, Dae-Won Lee, et al.Cancer Research and Treatment|August 6, 2021
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung AdenocarcinomaYen-Hsiang Huang, Kuo-Hsuan Hsu, Chun-Shih Chin, et al.Cancer Research and Treatment|November 23, 2021
The Role of Neutrophil-to-Lymphocyte Ratio in Predicting Pathological Response for Resectable Non-Small Cell Lung Cancer Treated with Neoadjuvant Chemotherapy Combined with PD-1 Checkpoint InhibitorsXiaoyan Sun, Yingnan Feng, Bin Zhang, et al.Cancer Research and Treatment|November 23, 2021
The Value of the Illness-Death Model for Predicting Outcomes in Patients with Non-Small Cell Lung CancerKum Ju Chae, Hyemi Choi, Won Gi Jeong, et al.Pageof 229